Dupixent and Narrowband UVB for Atopic Dermatitis

Phase 4

Recruiting

• Conditions: Atopic Dermatitis
• Interventions: Drug: Dupixent

• Registration Number: NCT05285839
• Lead Sponsor: Psoriasis Treatment Center of Central New Jersey

Brief Summary

24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

Detailed Description

24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

Study Timeline

• Study First Submitted: 2022-03-08
• Study First Submitted QC: 2022-03-08
• Study First Posted: 2022-03-18
• Study Start: 2022-04-19
• Status Verified: 2024-03
• Last Update Submitted: 2024-03-14
• Last Update Posted: 2024-03-15
• Primary Completion: 2024-12-01
• Study Completion: 2024-12-15

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Male or female adult ≥ 18 years of age;

• Diagnosis of moderate to severe atopic dermatitis as defined at baseline by:

  • EASI score of 16 or greater,
  • IGA score of 3 or greater
  • BSA of 10% or greater,

Exclusion Criteria

• Subjects with previous exposure to dupilumab.
• Known or suspected hypersensitivity to dupilumab or any of its excipients.
• History of photosensitivity.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Dupixent and Narrowband UVB	Dupixent	Dupixent and Narrowband UVB

Primary Outcome Measures

Name	Time	Method
Investigators Global Assessment Score of score of 0 or 1	12 weeks	Proportion of subjects achieving an IGA score of 0 or 1 with at least a 2 grade improvement at week 12

Trial Locations

Locations (1)

Eczema Treatment Center of New Jersey; 🇺🇸 East Windsor, New Jersey, United States